Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
J Diabetes Investig. 2021 Jul;12(7):1272-1277. doi: 10.1111/jdi.13457. Epub 2020 Dec 2.
J Diabetes Investig. 2021.
PMID: 33131199
Free PMC article.
Clinical Trial.